Effective examination methods for identifying the primary origins of metastatic bone tumors of unknown primary origin during the initial visit: A retrospective chart review study.
Neoplasms
bone
diagnosis
metastasis
unknown primary
Journal
SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
01
2022
accepted:
12
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
To provide appropriate treatment for patients, early diagnosis of the primary origin of skeletal metastases of unknown primary origin is important. This study aimed to assess the examination strategy effective for identifying the primary origin of skeletal metastases of unknown primary origin. Sixty-one patients with skeletal metastases of unknown primary origin were reviewed. The primary origin was examined via physical examination, blood test including tumor markers, chest radiography, thoracoabdominal computed tomography scan, positron emission tomography-computed tomography scan, metastatic lesion biopsy, and other assessments. Examination methods considered effective for the diagnosis of the primary origin in a specific type of cancer were investigated. The lung was the most common primary origin site, followed by the lymph nodes, prostate, and breast. Meanwhile, biopsy was the most effective examination, followed by positron emission tomography-computed tomography scan and thoracoabdominal computed tomography scan. Blood tests are useful for detecting hematological malignancies and prostate cancer. Computed tomography scans can be used to identify cancers in the lung, breast, and kidney, which are the common primary origins. Forty-one (67.2%) of the 61 patients with skeletal metastases of unknown primary origin were diagnosed via the first four steps, that is, physical examination, blood test, chest radiography, and thoracoabdominal computed tomography scan. Finally, two patients were diagnosed with skeletal metastases of unknown primary origin. The examination steps used in this study, including physical examination, blood test including tumor markers, chest radiography, thoracoabdominal computed tomography scan, positron emission tomography-computed tomography scan, biopsy, and other assessments were effective in determining the primary origin of skeletal metastases of unknown primary origin during the initial visit.
Identifiants
pubmed: 35646367
doi: 10.1177/20503121221097582
pii: 10.1177_20503121221097582
pmc: PMC9136433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20503121221097582Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Nippon Med Sch. 2018;85(5):271-278
pubmed: 30464144
Cancer. 1999 Aug 1;86(3):533-7
pubmed: 10430264
Br J Cancer. 2015 Sep 1;113(5):848-60
pubmed: 26241817
Crit Rev Oncol Hematol. 2009 Mar;69(3):271-8
pubmed: 18977667
Front Oncol. 2020 Jan 17;9:1546
pubmed: 32010631
Int Orthop. 1989;13(2):119-23
pubmed: 2744913
PLoS One. 2015 Jun 26;10(6):e0129428
pubmed: 26115010
J Bone Joint Surg Am. 2009 Jun;91(6):1518-30
pubmed: 19487533
World J Nucl Med. 2016 May-Aug;15(2):124-9
pubmed: 27134563
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46
pubmed: 29700092
Hematology. 2015 Jan;20(1):58-9
pubmed: 25602931
Int J Cancer. 2018 Feb 15;142(4):741-746
pubmed: 29023685
BMJ. 2014 Nov 10;349:g4797
pubmed: 25385470
Med Clin North Am. 2017 Jul;101(4):769-785
pubmed: 28577626
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
PLoS One. 2013 Nov 13;8(11):e78730
pubmed: 24236041
Mol Clin Oncol. 2014 Sep;2(5):875-881
pubmed: 25054061
CA Cancer J Clin. 2017 Mar;67(2):100-121
pubmed: 28170086
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Indian J Surg Oncol. 2018 Mar;9(1):46-51
pubmed: 29563734
PLoS One. 2018 May 10;13(5):e0196808
pubmed: 29746513
J Clin Oncol. 2008 Sep 20;26(27):4373-5
pubmed: 18802148